Table 1. Significantly Perturbed Lipids in the K. pneumoniae FADDI-KP070 Metabolome Following Treatment with Ceftazidime/Avibactam (log2 FC ≥ 0.59 or ≤ −0.59, p < 0.05).
| lipid intermediates |
log2FC |
|||||
|---|---|---|---|---|---|---|
| lipid | class | formula | mass | 1 h | 3 h | 6 h |
| palmitic acid | lipid | C16H32O2 | 256.4 | 3.26 | ||
| phosphatidic acid | lipid | C5H7O8PR2 | 226.07 | –2.76 | ||
| tetradecanoic acid | lipid | C14H28O2 | 228.20 | 2.03 | ||
| (R)-3-hydroxybutanoate | lipid | C4H8O3 | 104.04 | –1.00 | ||
| (9Z)-hexadecenoic acid | lipid | C16H30O2 | 254.22 | 4.26 | ||
| sn-glycerol 3-phosphate | lipid | C3H9O6P | 172.01 | 6.18 | ||
| heptaprenyl diphosphate | lipid | C35H60O7P2 | 654.38 | –2.80 | –2.91 | |
| FA (12:1) | FAs | C12H24O | 184.18 | –1.98 | ||
| FA (20:4) | FAs | C20H32O2 | 304.24 | –3.40 | ||
| FA oxo(5:0) | FAs | C5H8O3 | 116.04 | –3.32 | ||
| 2-butenoate | FAs | C4H6O2 | 86.036 | –4.76 | ||
| FA hydroxy(4:0) | FAs | C8H13NO4 | 187.08 | –3.38 | ||
| FA hydroxy(6:0) | FAs | C6H12O3 | 132.07 | –3.42 | ||
| FA hydroxy(9:0) | FAs | C9H18O3 | 174.12 | 1.34 | ||
| FA methyl(16:1) | FAs | C17H32O2 | 268.24 | 6.78 | ||
| 5-hydroxypentanoate | FAs | C5H10O3 | 118.06 | –3.81 | ||
| formyl-3-hydroxybutanoate | FAs | C5H10O3 | 118.06 | –3.16 | ||
| 2-amino-4-methylpentanoic | FAs | C6H13NO2 | 131.09 | –1.99 | ||
| 2-C-methyl-d-erythritol-4P | FAs | C5H13O7P | 216.04 | –3.18 | ||
| PS(18:1) | GPLs | C24H46NO9P | 523.29 | –2.14 | –5.49 | |
| PS(18:0) | GPLs | C24H48NO9P | 525.30 | –5.41 | ||
| PI(33:2) | GPLs | C42H77O13P | 842.48 | –5.11 | ||
| PI(18:2) | GPLs | C27H49O12P | 596.29 | –4.73 | ||
| PI(18:1) | GPLs | C27H51O12P | 598.31 | –4.64 | ||
| PI(16:0) | GPLs | C25H49O12P | 572.29 | –4.51 | ||
| PG(35:1) | GPLs | C41H79O10P | 762.54 | –5.84 | ||
| PG(37:2) | GPLs | C43H81O10P | 788.55 | –3.93 | ||
| PG(36:2) | GPLs | C42H79O10P | 774.54 | –3.91 | ||
| PG(35:2) | GPLs | C41H77O10P | 760.52 | –3.79 | ||
| PG(34:2) | GPLs | C40H75O10P | 746.51 | –3.78 | ||
| PG(34:1) | GPLs | C40H77O10P | 748.52 | –3.74 | ||
| PG(33:1) | GPLs | C39H75O10P | 734.50 | –3.71 | ||
| PG(32:2) | GPLs | C38H71O10P | 718.47 | –3.59 | ||
| PG(32:1) | GPLs | C38H73O10P | 720.49 | –3.38 | ||
| PG(31:1) | GPLs | C37H71O10P | 706.47 | –3.34 | ||
| PG(30:1) | GPLs | C36H69O10P | 692.46 | –3.32 | ||
| PG(30:0) | GPLs | C36H71O10P | 694.47 | –3.32 | ||
| PG(19:1(9Z)/0:0) | GPLs | C25H49O9P | 524.31 | –3.19 | ||
| PG(17:1) | GPLs | C23H45O9P | 496.28 | –2.96 | ||
| PG (28:0) | GPLs | C34H67O10P | 666.44 | –2.91 | ||
| PG (16:0) | GPLs | C22H45O9P | 484.28 | –2.87 | ||
| PE(36:2) | GPLs | C41H78NO8P | 743.54 | –1.50 | –2.84 | |
| PE(34:1) | GPLs | C39H76NO8P | 717.53 | –2.83 | ||
| PE(30:1) | GPLs | C35H68NO8P | 661.46 | –2.06 | –2.75 | |
| PE(30:0) | GPLs | C35H70NO8P | 663.48 | –2.70 | ||
| PE(28:0) | GPLs | C33H66NO8P | 635.45 | –2.69 | ||
| PC(6:2) | GPLs | C14H32NO6P | 341.19 | –2.53 | ||
| PC(32:2) | GPLs | C40H76NO8P | 729.53 | –2.51 | ||
| PC(32:1) | GPLs | C40H78NO8P | 731.54 | –2.51 | ||
| PC(30:1) | GPLs | C38H74NO8P | 703.51 | –2.41 | ||
| PA(30:1) | GPLs | C33H63O8P | 618.42 | –2.38 | ||
| PA(30:0) | GPLs | C33H65O8P | 620.44 | –2.11 | ||
| PA(16:0/0:0) | GPLs | C19H39O7P | 410.24 | –1.96 | ||
| PA(14:0/0:0) | GPLs | C17H35O7P | 382.21 | –0.94 | ||
| lysoPE(18:2) | GPLs | C23H44NO7P | 477.28 | –0.87 | ||
| lysoPE(18:0) | GPLs | C23H48NO7P | 481.31 | 1.05 | ||
| lysoPE(0:0/14:0) | GPLs | C19H40NO7P | 425.25 | 1.45 | ||
| lysoPC(16:1(9Z)) | GPLs | C24H48NO7P | 493.31 | 1.64 | 1.90 | |
| lysoPC(16:0) | GPLs | C24H50NO7P | 495.33 | 4.10 | 2.27 | |
| lysoPC(14:1) | GPLs | C22H44NO7P | 465.28 | 2.47 | ||
FAs, fatty acids; GPLs, glycerophospholipids; PE, phosphoethanolamines; PG, glycerophosphoglycerols; PS, glycerophosphoserines; PC, glycerophosphocholines; PA, glycerophosphates; PI, glycerophosphoinositols; LysoPE, lysophosphatidylethanolamines; and lysoPC, lysophosphatidylcholines.